Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: Comparison with immunodominant peptide-pulsed DCs

Oncology

Volumn 68, Issue 2-3, 2005, Pages 163-170

  Nakamura, Masaki ^a   Iwahashi, Makoto ^a   Nakamori, Mikihito ^a   Ueda, Kentaro ^a   Ojima, Toshiyasu ^a   Naka, Teiji ^a   Ishida, Koichiro ^a   Yamaue, Hiroki ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Adenovirus vector; CCR7; CD4+ T cell response; Dendritic cells; gp70; Immunodominant peptide

Indexed keywords

ADENOVIRUS VECTOR; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; DENDRITIC CELL VACCINE; EPITOPE; GAMMA INTERFERON; GLYCOPROTEIN GP 70; PEPTIDE; SERYLPROLYLSERYLTYROSYLVALYLTYROSYLHISTIDYLGLUTAMINYLPHENYLALANINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; CANCER VACCINE; GLYCOPROTEIN; GLYCOPROTEIN GP70, MURINE SERUM; PEPTIDE FRAGMENT;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; COLORECTAL CARCINOMA; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; DRUG POTENCY; FEMALE; GASTROINTESTINAL TUMOR; GENE EXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VIVO STUDY; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; SPLEEN CELL; TUMOR CELL; TUMOR IMMUNITY; VACCINATION; ADENOCARCINOMA; ADENOVIRUS; ANIMAL; BAGG ALBINO MOUSE; CD4+ T LYMPHOCYTE; COLORECTAL TUMOR; GENETICS; IMMUNOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; ADENOVIRIDAE; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DENDRITIC CELLS; FEMALE; GLYCOPROTEINS; HUMANS; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; TRANSDUCTION, GENETIC;

EID: 23844480879     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086770     Document Type: Article

References (32)

1. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-1647.
2. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Appella E, Rosenberg SA: Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994;180:347-352.
3. Nukaya I, Yasumoto M, Iwasaki T, Ideno M, Sette A, Celis E, Takesako K, Kato I: Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte. Int J Cancer 1999;80:92-97.
4. Tanaka H, Tsunoda T, Nukaya I, Sette A, Mastuda K, Umano Y, Yamaue H, Takesako K, Tanimura H: Mapping the HLA-A24-restricted T-cell epitope peptide from a tumor-associated antigen HER2/neu: Possible immunotherapy for colorectal carcinomas. Br J Cancer 2001;84:94-99.
5. Umano Y, Tsunoda T, Tanaka H, Matsuda K, Yamaue H, Tanimura H: Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53. Br J Cancer 2001;84:1052-1057.
6. Steinman RM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271-296.
7. Hart DNJ: Dendritic cells: Unique leukocyte populations which control the primary immune response. Blood 1997;90:3245-3287.
8. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-332.
9. Morse MA, Deng Y, Coleman D, Hull S, Kitrell-Fisher E, Nair S, Schlom J, Ryback ME, Lyerly HK: A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 1999;5:1331-1338.
10. Burch PA, Breen JK, Buckner JC, Gastineau DA, Kaur JA, Laus RL, Padley DJ, Peshwa MV, Pitot HC, Richardson RL, Smits BJ, Sopapan P, Strang G, Valone FH, Vuk-Pavlovic S: Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 2000;6:2175-2182.
11. Matsuda K, Tsunoda T, Tanaka H, Umano Y, Tanimura H, Nukaya I, Takesako K, Yamaue H: Enhancement of cytotoxic T-lymphocyte responses in patients with gastrointestinal malignancies following vaccination with CEA peptide-pulsed dendritic cells. Cancer Immunol Immunother 2004;53:609-616.
12. Song W, Kong HL, Carpenter H, Torii H, Granstein R, Rafii S, Moore MAS, Crystal RG: Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 1997;186:1247-1256.
13. Ribas A, Butterfield LH, McBride WH, Jilani SM, Bui LA, Vollmer CM, Lau R, Dissette VB, Hu B, Chen AY, Glaspy JA, Economou JS: Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cancer Res 1997;57:2865-2869.
14. Kaplan JM, Yu Q, Piraino ST, Pennington SE, Shankara S, Woodworth LA, Roberts BL: Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J Immunol 1999;163:699-707.
15. + T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene. Cancer Res 1998;58:5305-5309.
16. Diebold SS, Cotton M, Koch N, Zenke M: MHC class II presentation of endogenously expressed antigens by transfected dendritic cells. Gene Ther 2001;8:487-493.
17. Nakamura M, Iwahashi M, Nakamori M, Ueda K, Matsuura I, Noguchi K, Yamaue H: Dendritic cells genetically engineered to simultaneously express endogenous tumor antigen and granulocyte macrophage colony-stimulating factor elicit potent therapeutic antitumor immunity. Clin Cancer Res 2002;8:2742-2749.
18. Huang AYC, Gulden PH, Woods AS, Thomas MC, Tong CD, Wang W, Engelhard VH, Pasternack G, Cotter R, Hunt D, Pardoll DM, Jaffee EM: The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci USA 1996;93:9730-9735.
19. Lutz MB, Kukutsch N, Ogilvie ALJ, Rössner S, Koch F, Romani N, Schuler G: An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999;223:77-92.
20. Ueda K, Iwahashi M, Nakamori M, Nakamura M, Yamaue H, Tanimura H: Enhanced selective gene expression by adenovirus vector using Cre/loxP regulation system for human carcinoembryonic antigen-producing carcinoma. Oncology 2000;59:255-265.
21. Ueda K, Iwahashi M, Nakamori M, Nakamura M, Matsuura I, Yamaue H, Tanimura H: Carcinoembryonic antigen-specific suicide gene therapy of cytosine deaminase/5-fluorocytosine enhanced by the Cre/loxP system in the orthotopic gastric carcinoma model. Cancer Res 2001;61:6158-6162.
22. Iwahashi M, Tanimura H, Yamaue H, Tsunoda T, Tani M, Tamai M, Noguchi K, Hotta T: Defective autologous mixed lymphocyte reaction (AMLR) and killer activity generated in the AMLR in cancer patients. Int J Cancer 1992;51:67-71.
23. Terasawa H, Tanimura H, Nakamori M, Tsunoda T, Iwahashi M, Tani M, Yamaue H: Antitumor effects of interleukin-2 gene-modified fibroblasts in an orthotopic colon cancer model. Jpn J Cancer Res 1999;90:1000-1006.
24. + T cell-dependent mechanism. Gene Ther 2001;8:1255-1263.
25. Yanagihara S, Komura E, Nagafune J, Watarai H, Yamaguchi Y: EBI1/CCR7 is a new member of dendritic cell chemokine receptor that is up-regulated upon maturation. J Immunol 1998;161:3096-3102.
26. Kellermann SA, Hudak S, Oldham ER, Liu YJ, McEvoy LM: The CC chemokine receptor-7 ligands 6Ckine and macrophage inflammatory protein-3β are potent chemoattractants for in vitro- and in vivo-derived dendritic cells. J Immunol 1999;162:3859-3864.
27. Chan VWF, Kothakota S, Rohan MC, Panganiban-Lustan L, Gardner JP, Wachowicz MS, Winter JA, Williams LT: Secondary lymphoid-tissue chemokine (SLC) is chemotactic for mature dendritic cells. Blood 1999;93:3610-3616.
28. Hirschowitz EA, Weaver JD, Hidalgo GE, Doherty DE: Murine dendritic cells infected with adenovirus vectors show signs of activation. Gene Ther 2000;7:1112-1120.
29. Song W, Tong Y, Carpenter H, Kong HL, Crystal RG: Persistent, antigen-specific, therapeutic antitumor immunity by dendritic cells genetically modified with an adenoviral vector to express a model tumor antigen. Gene Ther 2000;7:2080-2086.
30. d-restricted T cell epitopes on living cells. Eur J Immunol 1996;26:1993-1999.
31. Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T, Miyake K, Freudenberg M, Galanos C, Simon JC: Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 2002;195:99-111.
32. Klein C, Bueler H, Mulligan RC: Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J Exp Med 2000;191:1699-1708.